Literature DB >> 8268366

European guidelines for anti-infective drug products. Introduction.

T R Beam1, D N Gilbert, C M Kunin.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8268366     DOI： 10.1093/clinids/17.4.787

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  3 in total

1.  Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.

Authors:  G Zanetti; F Bally; G Greub; J Garbino; T Kinge; D Lew; J-A Romand; J Bille; D Aymon; L Stratchounski; L Krawczyk; E Rubinstein; M-D Schaller; R Chiolero; M-P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.

Authors:  J S Solomkin; H H Reinhart; E P Dellinger; J M Bohnen; O D Rotstein; S B Vogel; H H Simms; C S Hill; H S Bjornson; D C Haverstock; H O Coulter; R M Echols
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

3.  Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.

Authors:  R Finch; D Schürmann; O Collins; R Kubin; J McGivern; H Bobbaers; J L Izquierdo; P Nikolaides; F Ogundare; R Raz; P Zuck; G Hoeffken
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.